MiniMed to Engage in Significant Investor Conferences in December 2026
In a notable development for the healthcare and investor community, MiniMed (Nasdaq: MMED), recognized globally for its innovative diabetes technology, has announced its participation in several key investor conferences this December. Chad Spooner, the company’s Executive Vice President and Chief Financial Officer, will lead discussions at these gatherings, addressing critical topics and answering questions concerning MiniMed's strategic direction and latest initiatives.
The specific conferences include:
- Time: 10:50 a.m. EST / 7:50 a.m. PST
- Time: 11:00 a.m. EST / 8:00 a.m. PST
- Time: 11:30 a.m. EST / 8:30 a.m. PST
For those unable to attend in person, live webcasts of each event will be available for streaming through MiniMed's Investor Relations website. Replays will also be accessible after each session, ensuring that all interested stakeholders can stay informed about the discussion and insights shared during these pivotal conferences.
MiniMed has built a reputation over its 40 years of experience for being at the forefront of diabetes care. The company is dedicated to advancing therapies that enhance the lives of individuals with diabetes across more than 80 countries. Their comprehensive ecosystem integrates insulin delivery systems with continuous glucose monitoring (CGM) technologies, algorithms, and a user-friendly application designed to work in harmony. This approach is complemented by exceptional service and support.
The company’s mission reinforces its commitment to improving the daily lives of those managing diabetes through reliable therapies that alleviate burdens and improve overall quality of life. As MiniMed prepares for these investor conferences, it aims to further communicate its ongoing innovations and highlight its readiness to tackle the challenges faced by individuals living with diabetes.
While MiniMed is progressing with robust plans and established credibility, it also acknowledges that forward-looking statements are inherently subject to risks and uncertainties, as noted in the periodic reports filed with the Securities and Exchange Commission. Stakeholders are reminded that actual results may vary significantly from projected outcomes, owing to a variety of market and operational factors.
As the dates for these influential conferences approach, the anticipation among investors and the healthcare community grows. MiniMed's insights will no doubt help establish a clearer vision of the company’s trajectory and the future of diabetes care technology, reinforcing its stature as an innovator in this vital field.
The specific conferences include:
- - 9th Annual Evercore Healthcare Conference
- Time: 10:50 a.m. EST / 7:50 a.m. PST
- - Citi's 2026 Global Healthcare Conference
- Time: 11:00 a.m. EST / 8:00 a.m. PST
- - Piper Sandler 38th Annual Healthcare Conference
- Time: 11:30 a.m. EST / 8:30 a.m. PST
For those unable to attend in person, live webcasts of each event will be available for streaming through MiniMed's Investor Relations website. Replays will also be accessible after each session, ensuring that all interested stakeholders can stay informed about the discussion and insights shared during these pivotal conferences.
MiniMed has built a reputation over its 40 years of experience for being at the forefront of diabetes care. The company is dedicated to advancing therapies that enhance the lives of individuals with diabetes across more than 80 countries. Their comprehensive ecosystem integrates insulin delivery systems with continuous glucose monitoring (CGM) technologies, algorithms, and a user-friendly application designed to work in harmony. This approach is complemented by exceptional service and support.
The company’s mission reinforces its commitment to improving the daily lives of those managing diabetes through reliable therapies that alleviate burdens and improve overall quality of life. As MiniMed prepares for these investor conferences, it aims to further communicate its ongoing innovations and highlight its readiness to tackle the challenges faced by individuals living with diabetes.
While MiniMed is progressing with robust plans and established credibility, it also acknowledges that forward-looking statements are inherently subject to risks and uncertainties, as noted in the periodic reports filed with the Securities and Exchange Commission. Stakeholders are reminded that actual results may vary significantly from projected outcomes, owing to a variety of market and operational factors.
As the dates for these influential conferences approach, the anticipation among investors and the healthcare community grows. MiniMed's insights will no doubt help establish a clearer vision of the company’s trajectory and the future of diabetes care technology, reinforcing its stature as an innovator in this vital field.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.